Have you already looked at
Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: time series analysis -- Hawton et al. 338: b2270 -- BMJ
Suicides haven't transferred successfully to other analgesics - though they might be throwing themselves off cliffs or under trains.
I'm with you about replacements for co-proxamol not always being as effective
Co-proxamol: where have all the patients gone? -- Ottewell and Walker 47 (3): 375 -- Rheumatology
But the political decision was made that a target was a reduction in suicides - to this end the means of suicide have been curtailed. (It's cheaper and easier than looking at the reasons which drive a person to suicide)
To add insult to injury -
The European Medicines Agency (EMEA) has announced their
recommendation to withdraw the marketing authorisations for
dextropropoxyphene-containing medicines (including co-proxamol) across
the European Union (EU). This recommendation was made after the
Committee on Medicinal Products for Human Use (CHMP) concluded that
the risks, particularly of potentially fatal overdose, were greater
than the medicine’s benefits. The EMEA’s recommendation has been
forwarded to the European Commission (EC) for a decision which will be
legally binding across the EU. In the UK, the only medicine affected
by the EMEA's announcement is co-proxamol.
News Centre : MHRA
Jeff